BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35173276)

  • 1. Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.
    Nasir Kansestani A; Zare ME; Tong Q; Zhang J
    Sci Rep; 2022 Feb; 12(1):2623. PubMed ID: 35173276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase Test.
    Kim YC; Kim JH; Cheung DY; Kim TH; Jun EJ; Oh JW; Kim CW; Chung WC; Kim BW; Kim SS; Kim JI; Park SH; Kim JK
    Gut Liver; 2015 Sep; 9(5):641-8. PubMed ID: 25473070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of faecal tests for the detection of colon cancer: a new strategy for an appropriate selection of referrals to colonoscopy? A prospective multicentre Italian study.
    Parente F; Marino B; Ilardo A; Fracasso P; Zullo A; Hassan C; Moretti R; Cremaschini M; Ardizzoia A; Saracino I; Perna F; Vaira D
    Eur J Gastroenterol Hepatol; 2012 Oct; 24(10):1145-52. PubMed ID: 22735608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis.
    Tonus C; Sellinger M; Koss K; Neupert G
    World J Gastroenterol; 2012 Aug; 18(30):4004-11. PubMed ID: 22912551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic accuracy of one or two faecal haemoglobin and calprotectin measurements in patients with suspected colorectal cancer.
    Turvill J; Mellen S; Jeffery L; Bevan S; Keding A; Turnock D
    Scand J Gastroenterol; 2018 Dec; 53(12):1526-1534. PubMed ID: 30621475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer.
    Mulder SA; van Leerdam ME; van Vuuren AJ; Francke J; van Toorenenbergen AW; Kuipers EJ; Ouwendijk RJ
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):878-82. PubMed ID: 17873612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal biomarkers do not always identify pre-cancerous lesions in patients who present in primary care with bowel symptoms.
    Keenan J; Aitchison A; Leaman J; Pearson J; Frizelle F
    N Z Med J; 2019 Aug; 132(1501):48-56. PubMed ID: 31465327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
    Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
    Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.
    Kalimutho M; Del Vecchio Blanco G; Cretella M; Mannisi E; Sileri P; Formosa A; Pallone F; Federici G; Bernardini S
    Int J Colorectal Dis; 2011 May; 26(5):583-92. PubMed ID: 21225430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care Cohort.
    Bond AD; Burkitt MD; Sawbridge D; Corfe BM; Probert CS
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):71-7. PubMed ID: 27014756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
    Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
    Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification of symptomatic patients suspected of colorectal cancer using faecal and urinary markers.
    Widlak MM; Neal M; Daulton E; Thomas CL; Tomkins C; Singh B; Harmston C; Wicaksono A; Evans C; Smith S; Savage RS; Covington JA; Arasaradnam RP
    Colorectal Dis; 2018 Dec; 20(12):O335-O342. PubMed ID: 30248228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma.
    Tibble J; Sigthorsson G; Foster R; Sherwood R; Fagerhol M; Bjarnason I
    Gut; 2001 Sep; 49(3):402-8. PubMed ID: 11511563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum.
    Rutka M; Bor R; Bálint A; Fábián A; Milassin Á; Nagy F; Szepes Z; Szűcs M; Tiszlavicz L; Farkas K; Molnár T
    Mediators Inflamm; 2016; 2016():2492081. PubMed ID: 27413251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study.
    Haug U; Hundt S; Brenner H
    Br J Cancer; 2008 Jul; 99(1):133-5. PubMed ID: 18542075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase.
    Caviglia GP; Cabianca L; Fagoonee S; Gili FM
    Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients.
    Widlak MM; Thomas CL; Thomas MG; Tomkins C; Smith S; O'Connell N; Wurie S; Burns L; Harmston C; Evans C; Nwokolo CU; Singh B; Arasaradnam RP
    Aliment Pharmacol Ther; 2017 Jan; 45(2):354-363. PubMed ID: 27910113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of faecal M2-PK and FIT in a population-based bowel cancer screening cohort.
    Leen R; Seng-Lee C; Holleran G; O'Morain C; McNamara D
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):514-8. PubMed ID: 24699725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy of fecal calprotectin for screening patients with colorectal cancer: A meta-analysis.
    Ye X; Huai J; Ding J
    Turk J Gastroenterol; 2018 Jul; 29(4):397-405. PubMed ID: 30249553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
    Högberg C; Karling P; Rutegård J; Lilja M
    Scand J Gastroenterol; 2017 Jan; 52(1):69-75. PubMed ID: 27623716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.